Clinical Trials for Patients with Histiocytic Malignancies

Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients with Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

This is an all-oral, non-chemotherapy phase 1b clinical trial open at Mayo Clinic, MN. Eligible patients are those who have received frontline treatment.  This study is based on our discovery of a novel drug combination in the laboratory, translating research findings to patient care.

For more information please contact:

Jithma P. Abeykoon, M.D.
abeykoon.jithma@mayo.edu

Ronald S. Go, M.D.
go.ronald@mayo.edu

View the Preclinical Studies
ClinicalTrials.gov ID: NCT04640779

Q702 for the Treatment of Patients With Hematologic Malignancies

This is an all-oral, non-chemotherapy phase 1b clinical trial, scheduled to open at Mayo Clinic, MN in August 2025. Eligible patients include those with histiocytic cancers who have previously undergone treatment or who cannot tolerate or afford standard frontline therapies.  This is an investigator-initiated clinical trial from Mayo Clinic, where the effectiveness of CSF1R inhibitors was documented for the first time in a patient with Erdheim-Chester disease. This study aims to evaluate the efficacy of CSF 1R inhibitors in patients with histiocytic malignancies through a phase 1 clinical trial.

For more information please contact:

Mayo Clinic:
Jithma Abeykoon: abeykoon.jithma@mayo.edu
Ronald Go: go.ronald@mayo.edu

UAB:
Gaurav Goyal: ggoyal@uabmc.edu

ClinicalTrials.gov ID: NCT06712810

Ulixertinib for the Treatment of Patients with Relapsed or Refractory Histiocytic Neoplasms

This is a multicenter, all-oral, non-chemotherapy clinical trial for patients with histiocytic cancers who have already been treated with frontline therapy.

Additional Locations: This clinical trial will also be available at Mayo Clinic AZ and the University of Alabama at Birmingham in the near future.

For more information please contact:

Mayo Clinic:
Jithma Abeykoon: abeykoon.jithma@mayo.edu
Ronald Go: go.ronald@mayo.edu 

UAB:
Gaurav Goyal: ggoyal@uabmc.edu

View the Preclinical Studies
ClinicalTrials.gov ID: NCT06411821

Histio-Care Network is unable to provide reimbursement for indirect costs, facilities and administrative (F&A) costs, or institutional overhead. All funds provided through Histio-Care Network must be applied directly to the approved project, program, or research activities.

HOME       MEMBERS       CLINICAL RESOURCES       PATIENT RESOURCES       RESEARCH       CONTACT       DONATE

The Histio-Care Network is a nonprofit organization recognized as tax-exempt under Section 501(c)(3) of the Internal Revenue Code. EIN: 42-2925285. Contributions may be tax-deductible to the extent permitted by law.

Located at 8056 Baird Rd. Groveport, Ohio 43125